Form 8-K - Current report:
SEC Accession No. 0001711279-24-000065
Filing Date
2024-12-18
Accepted
2024-12-18 08:39:33
Documents
14
Period of Report
2024-12-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krys-20241218.htm   iXBRL 8-K 32712
2 EX-99.1 cancerdataannouncementfinal.htm EX-99.1 17161
  Complete submission text file 0001711279-24-000065.txt   170896

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20241218.xsd EX-101.SCH 1791
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT krys-20241218_lab.xml EX-101.LAB 20073
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT krys-20241218_pre.xml EX-101.PRE 11516
16 EXTRACTED XBRL INSTANCE DOCUMENT krys-20241218_htm.xml XML 2537
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38210 | Film No.: 241557770
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)